Loading viewer...
investor_presentation
Format: PDF investor_presentation
JP Morgan Healthcare Conference 2020 Michael G. Kauffman, MD, PhD, Chief Executive Officer January 14, 2020
JP Morgan Healthcare Conference 2020
Michael G. Kauffman, MD, PhD, Chief Executive Officer
January 14, 2020 2 ©2020 Karyopharm Therapeutics Inc. This presentation contains forward -looking statements within themeaning ofthe“safe harbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such forward-
looking statements include those regarding Karyopharm’s expectations relating toXPOVIO®forthetreatment ofpatients with heavily pretreated multiple myeloma ;thetherapeutic
potential ofandpotential clinical development plans andcommercialization forKaryopharm’s drug candidates, including thetiming ofinitiation ofcertain trials, ofthereporting of
data from such trials, ofthesubmissions toregulatory authorities andofpotential commercial launches ;thepotential availability ofaccelerated approval pathways ;thepotential size
ofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment ofpatients withrelapsed multiple myeloma; thepotential sizeofthemarkets fordiffuse large B-
celllymphoma (DLBCL) drugs andDLBCL drugs fortreatments ofpatients withrelapsed and/or refractory DLBCL ;andKaryopharm’s strategic andfinancial plans andexpectations,
aswellasfinancial projections forKaryopharm .Such statements aresubject tonumerous important factors, risks anduncertainties thatmay cause actual events orresults todiffer
materially from Karyopharm’s current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO, thatregulators willagree
thatselinexor qualifies forconditional approval intheE.U.asaresult ofthedata from theSTORM study inpatients with penta- refractory myeloma oraccelerated approval inthe
U.S.based ontheSADAL study inpatients with relapsed/refractory DLBCL orthat any ofKaryopharm’s drug candidates, including selinexor and eltanexor (KPT -8602),
Karyopharm’s second generation SINE compound, orKPT-9274, Karyopharm’s first-in -class oraldual inhibitor ofPAK4 andNAMPT, oranyother drug candidate Karyopharm is
developing, willsuccessfully complete necessary preclinical andclinical development phases orthatdevelopment ofanyofKaryopharm’s drug candidates willcontinue. Further,
there canbenoguarantee thatanypositive developments inKaryopharm’s drug candidate portfolio willresult instock price appreciation. Inaddition, even ifKaryopharm receives
marketing approval forselinexor inadditional indications orforanyother drug candidate, there canbenoassurance thatKaryopharm willbeable tosuccessfully commercialize that
drug candidate .Management’s expectations and, therefore ,anyforward -looking statements inthispresentation could also beaffected byrisks and uncertainties relating toa
number ofother factors, many ofwhich arebeyond Karyopharm’s control, including thefollowing :thetiming andcosts involved incommercializing XPOVIO oranyofKaryopharm’s
drug candidates thatreceive regulatory approval ;theability toretain regulatory approval ofXPOVIO oranyofKaryopharm’s drug candidates thatreceive regulatory approval ;
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
20 Pages
CenterPoint Energy
Kirloskar Oil Engines Investor Presentation September 2023
investor_presentationinvestor_presentation
14 Pages
Kirloskar Oil Engines Limited